Entities / Company
Soleno Therapeutics (United States).
company in Redwood City, United States
- Reports this week
- 0
- Active events
- 1
- Connections
- 43
What's happening
Gone quiet
No new reports in 90+ days-
Soleno Therapeutics filed an offering on July 10, 2025, with TD Cowen and Cantor as joint book-running managers, and the SEC (Bangladesh) was involved.Some support1 report
-
Soleno Therapeutics is developing therapeutics for rare diseases, including Prader-Willi Syndrome, and Anish Bhatnagar serves as CEO and Chairman of the Board.Speculative2 reports
-
TD Cowen began coverage of Soleno Therapeutics with a Buy rating on June 27, 2025.Speculative1 report
-
Soleno Therapeutics announced presentations at the Endocrine Society Annual Meeting on July 1, 2025.Speculative1 report
-
Soleno Therapeutics received a Zacks Rank of #2 (Buy) and a Momentum Style Score of A on July 26, 2025.Some support2 reports
-
Soleno Therapeutics achieved FDA approval and submitted an MAA to the EMA for its drug VYKAT XR.Some support2 reports
-
Soleno Therapeutics, a company in the medical drugs industry, outperformed S&P 500 stock gains on August 7, 2025.Some support1 report
-
Zacks Rank indicated strong fundamentals and earnings estimate revisions for Soleno Therapeutics on August 11, 2025.Some support1 report
-
Analysts predict potential stock upside for Soleno Therapeutics based on price targets and positive earnings estimate revisions.Some support2 reports
-
The FDA approved VYKAT XR for Prader-Willi syndrome, while Scorpion Capital released a short report on Soleno Therapeutics comparing it to Zafgen's failure.Some support2 reports
-
RSI reading of 26.7 indicates oversold territory for Soleno Therapeutics.Some support1 report
-
Wells Fargo hosted a healthcare conference for Soleno Therapeutics on August 27, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Soleno Therapeutics (United States) this week
News at the entities that move Soleno Therapeutics (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Soleno Therapeutics (United States)
Connections
The 2 strongest of 43, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Anish Bhatnagar Structural
Anish Bhatnagar serves as the CEO and Chairman of Soleno Therapeutics.
-
FDA Structural
The FDA formally regulates Soleno Therapeutics' products, granting market approval for specific treatments.
History
Events by the month they beganJune 2026
13 events- AI stocks are benefiting from Trump-era tariffs, and Brian Schwartz maintained an Outperform rating on Workday on September 5th.
- Soleno Therapeutics filed an offering on July 10, 2025, with TD Cowen and Cantor as joint book-running managers, and the SEC (Bangladesh) was involved.
- Soleno Therapeutics is developing therapeutics for rare diseases, including Prader-Willi Syndrome, and Anish Bhatnagar serves as CEO and Chairman of the Board.
- TD Cowen began coverage of Soleno Therapeutics with a Buy rating on June 27, 2025.
- Soleno Therapeutics announced presentations at the Endocrine Society Annual Meeting on July 1, 2025.
- Soleno Therapeutics received a Zacks Rank of #2 (Buy) and a Momentum Style Score of A on July 26, 2025.
- Soleno Therapeutics achieved FDA approval and submitted an MAA to the EMA for its drug VYKAT XR.
- Soleno Therapeutics, a company in the medical drugs industry, outperformed S&P 500 stock gains on August 7, 2025.
- Zacks Rank indicated strong fundamentals and earnings estimate revisions for Soleno Therapeutics on August 11, 2025.
- Analysts predict potential stock upside for Soleno Therapeutics based on price targets and positive earnings estimate revisions.
- The FDA approved VYKAT XR for Prader-Willi syndrome, while Scorpion Capital released a short report on Soleno Therapeutics comparing it to Zafgen's failure.
- RSI reading of 26.7 indicates oversold territory for Soleno Therapeutics.
- Wells Fargo hosted a healthcare conference for Soleno Therapeutics on August 27, 2025.